SciSparc Gets Extended Timeline: What the Nasdaq SPRC Stock Price Rule Extension Means

liquidation_surfer · 2025-12-31T09:50:35+00:00

SciSparc Ltd. has received a second 180-day grace period from Nasdaq to raise its share price above $1.00 after missing its initial deadline. The company plans to restore its stock value or consider a reverse split, with a critical deadline set for July 14, 2025.

liquidation_surfer

2025-12-31 09:50:35

Abstract generation in progress

SciSparc Ltd. (Nasdaq: SPRC) received fresh breathing room from Nasdaq on January 14, 2025—a second 180-day grace period to fix its stock price problem. The company now has until July 14, 2025 to get its share price back above the $1.00 minimum bid threshold that the exchange requires.

The Compliance Challenge: How SPRC Fell Behind

The trouble started last July. On July 16, 2024, Nasdaq sent an official notification that SPRC’s ordinary shares had dropped below the $1.00 per-share minimum bid price over 30 consecutive trading days. That triggered a first compliance window: 180 calendar days to recover, ending January 13, 2025.

The company missed that deadline. Shares stayed depressed, so SPRC requested a second chance. Nasdaq approved it, granting an extension through mid-July 2025.

What This Extension Means for Trading

Here’s the critical part: there’s zero immediate impact on Nasdaq: SPRC trading or listing status. The stock continues trading on Nasdaq Capital Market under ticker SPRC without interruption. No delisting threat looms—yet. But if the share price doesn’t climb above $1.00 for at least 10 consecutive business days before July 14, SPRC faces real consequences.

Nasdaq reserves the right to demand the price stay above $1.00 for up to 20 business days (not just 10) before officially closing the compliance matter. This is a higher bar than the minimum standard suggests.

How SPRC Plans to Cure the Deficiency

SciSparc has explicitly stated its plan to Nasdaq: restore the share price through normal market recovery, or execute a reverse stock split if necessary. A reverse split—consolidating shares to artificially boost the per-share price—is a common tactical move when a company needs to hit exchange minimums quickly.

The Company Behind the Ticker

SciSparc is a specialty clinical-stage pharmaceutical developer focused on cannabinoid-based therapies for central nervous system disorders and rare diseases. Its drug pipeline includes:

SCI-110: targeting Tourette Syndrome and Alzheimer’s disease-related agitation
SCI-210: in development for autism and status epilepticus

The company also owns a controlling stake in a subsidiary that sells hemp seed oil products on Amazon, providing a revenue stream outside the core pharmaceutical business.

The Bottom Line

Nasdaq: SPRC shareholders have seven months to see if the market recovers the stock price naturally. If not, a reverse split could be coming. The real test arrives on or before July 14, 2025.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.